Search
Results: 18
Innovations in the quantitative virus outgrowth assay and its use in clinical trials.
A robust measure of the size of the latent HIV reservoir is essential to quantifying the effect of interventions designed to deplete the pool of reactivatable, replication competent proviruses. In addition to the ability to...
Does being on HIV antiretroviral therapy increase the risk of syphilis? An analysis of a large national cohort of MSM living with HIV in England 2009-2016.
Hester Allen, Peter Kirwan, Alison E Brown, Hamish Mohammed, Gwenda Hughes, Michael Marks, Valerie Delpech
Nov 12, 2020
OBJECTIVE: A resurgence in bacterial STIs, notably syphilis, among gay, bisexual and other men who have sex with men (MSM) has been detected in England. A Canadian modelling study postulated that antiretroviral therapy (ART) may...
HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries
Ravindra K Gupta, John Gregson, Neil Parkin, Hiwot Haile-Selassie, Amilcar Tanuri, Liliana Andrade Forero, Pontiano Kaleebu, Christine Watera, Avelin Aghokeng, Nicholus Mutenda, Janet Dzangare, San Hone, Zaw Zaw Hang, Judith Garcia, Zully Garcia, Paola Marchorro, Enrique Beteta, Amalia Giron, Raph Hamers, Seth Inzaule, Lisa M Frenkel, Michael H Chung, Tulio de Oliveira, Deenan Pillay, Kogie Naidoo, Ayesha Kharsany, Ruthiran Kugathasan, Teresa Cutino, Gillian Hunt, Santiago Avila Rios, Meg Doherty, Michael R Jordan, Silvia Bertagnolio
Oct 22, 2019
BACKGROUND: Pretreatment drug resistance in people initiating or re-initiating antiretroviral therapy (ART) containing non-nucleoside reverse transcriptase inhibitors (NNRTIs) might compromise HIV control in low-income and...
Dendritic cell immunotherapy followed by cART interruption during HIV-1 infection induces plasma protein markers of cellular immunity and neutrophil recruitment.
Henk-Jan van den Ham, Jason D Cooper, Jakub Tomasik, Sabine Bahn, Joeri L Aerts, Albert DME Osterhaus, Rob A Gruters, Arno C Andeweg, DC-TRN trial investigators
May 23, 2018
OBJECTIVES: To characterize the host response to dendritic cell-based immunotherapy and subsequent combined antiretroviral therapy (cART) interruption in HIV-1-infected individuals at the plasma protein level. DESIGN: An...
Human Immunodeficiency Virus-1 Viral Load Is Elevated in Individuals With Reverse-Transcriptase Mutation M184V/I During Virological Failure of First-Line Antiretroviral Therapy and Is Associated With Compensatory Mutation L74I.
BACKGROUND: M184V/I cause high-level lamivudine (3TC) and emtricitabine (FTC) resistance and increased tenofovir disoproxil fumarate (TDF) susceptibility. Nonetheless, 3TC and FTC (collectively referred to as XTC) appear to...
HIV antiretroviral compensatory mutation Drug Resistance Lamivudine Anti-HIV Agents CD4 Lymphocyte Count Drug Resistance Viral Drug Therapy Combination Emtricitabine HIV Infections HIV Reverse Transcriptase HIV-1 Humans Lamivudine Mutation Randomized Controlled Trials as Topic Reverse Transcriptase Inhibitors Tenofovir Treatment Failure Viral Load
T cell derived HIV-1 is present in the CSF in the face of suppressive antiretroviral therapy.
Gila Lustig, Sandile Cele, Farina Karim, Anne Derache, Abigail Ngoepe, Khadija Khan, Bernadett I Gosnell, Mahomed-Yunus S Moosa, Ntombi Ntshuba, Suzaan Marais, Prakash M Jeena, Katya Govender, John Adamson, Henrik Kløverpris, Ravindra K Gupta, Rohen Harrichandparsad, Vinod B Patel, Alex Sigal
Nov 09, 2021
HIV cerebrospinal fluid (CSF) escape, where HIV is suppressed in blood but detectable in CSF, occurs when HIV persists in the CNS despite antiretroviral therapy (ART). To determine the virus producing cell type and whether...
Predictors of first-line antiretroviral therapy failure among adults and adolescents living with HIV/AIDS in a large prevention and treatment program in Nigeria.
Nicaise Ndembi, Fati Murtala-Ibrahim, Monday Tola, Jibreel Jumare, Ahmad Aliyu, Peter Alabi, Charles Mensah, Alash'le Abimiku, Miguel E Quiñones-Mateu, Trevor A Crowell, Soo-Yon Rhee, Robert W Shafer, Ravindra Gupta, William Blattner, Manhattan E Charurat, Patrick Dakum
Nov 30, 2020
BACKGROUND: A substantial number of persons living with HIV (PLWH) in Nigeria do not experience durable viral suppression on first-line antiretroviral therapy (ART). Understanding risk factors for first-line treatment failure...
Predicted antiviral activity of tenofovir versus abacavir in combination with a cytosine analogue and the integrase inhibitor dolutegravir in HIV-1-infected South African patients initiating or failing first-line ART.
Anne Derache, Collins C Iwuji, Siva Danaviah, Jennifer Giandhari, Anne-Geneviève Marcelin, Vincent Calvez, Tulio de Oliveira, François Dabis, Deenan Pillay, Ravindra K Gupta
Oct 22, 2019
OBJECTIVES: The WHO recently recommended the use of a new first-line ART containing dolutegravir. We investigated the efficacy of NRTI backbones (tenofovir or abacavir with a cytosine analogue) in low- and middle-income...
Adult Anti-HIV Agents Antiretroviral Therapy Highly Active Cytosine Dideoxynucleosides Drug Combinations Drug Resistance Viral Female HIV Infections HIV Integrase Inhibitors HIV-1 Heterocyclic Compounds 3-Ring Humans Male Middle Aged Mutation Oxazines Piperazines Pyridones South Africa Tenofovir Viral Load Young Adult
Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase.
Mark J Siedner, Michelle A Moorhouse, Bryony Simmons, Tulio de Oliveira, Richard Lessells, Jennifer Giandhari, Stephen A Kemp, Benjamin Chimukangara, Godspower Akpomiemie, Celicia M Serenata, Willem DF Venter, Andrew Hill, Ravindra K Gupta
Dec 07, 2020
Little is known about the impact of pretreatment drug resistance (PDR) on the efficacy of second generation integrase inhibitors. We sequenced pretreatment plasma specimens from the ADVANCE trial (NCT03122262). Our primary...
An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir.
Eva Agnes Odongpiny Laker, Maria Sarah Nabaggala, Arvind Kaimal, Damalie Nalwanga, Barbara Castelnuovo, Abdu Musubire, Agnes Kiragga, Mohammed Lamorde, Rosalind Parkes- Ratanshi
Sep 06, 2019
BACKGROUND: The World Health Organisation approved boosted atazanavir as a preferred second line protease inhibitor in 2010. This is as an alternative to the current boosted lopinavir. Atazanavir has a lower genetic barrier than...
Co-administration of fluconazole increases nevirapine concentrations in HIV-infected Ugandans.
Katie Wakeham, Rosalind Parkes-Ratanshi, Victoria Watson, Abu-Baker Ggayi, Saye Khoo, David G Lalloo
Apr 09, 2019
BACKGROUND: Data from retrospective studies have suggested that there may be an interaction between fluconazole and nevirapine, increasing nevirapine concentrations and potentially leading to hepatotoxicity. METHODS: This study...
Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa
Andrew N Phillips, Loveleen Bansi-Matharu, Francois Venter, Diane Havlir, Anton Pozniak, Daniel R Kuritzkes, Annemarie Wensing, Jens D Lundgren, Deenan Pillay, John Mellors, Valentina Cambiano, Andreas Jahn, Tsitsi Apollo, Owen Mugurungi, David Ripin, Juliana Da Silva, Elliot Raizes, Nathan Ford, George K Siberry, Ravindra K Gupta, Ruanne Barnabas, Paul Revill, Jennifer Cohn, Alexandra Calmy, Silvia Bertagnolio
Mar 16, 2020
BACKGROUND: The integrase inhibitor dolutegravir is being considered in several countries in sub-Saharan Africa instead of efavirenz for people initiating antiretroviral therapy (ART) because of superior tolerability and a lower...
Adolescent Adult Africa South of the Sahara Alkynes Anti-HIV Agents Benzoxazines Cost-Benefit Analysis Cyclopropanes Female HIV Infections Heterocyclic Compounds 3-Ring Humans Infectious Disease Transmission Vertical Male Middle Aged Oxazines Piperazines Practice Guidelines as Topic Pregnancy Pregnancy Complications Pyridones Randomized Controlled Trials as Topic Young Adult
Protease and gag diversity and drug resistance mutations among treatment-naive Mexican people living with HIV.
Samantha Climaco-Arvizu, Víctor Flores-López, Carolina González-Torres, Francisco Javier Gaytán-Cervantes, María Concepción Hernández-García, Paola Berenice Zárate-Segura, Monserrat Chávez-Torres, Emiliano Tesoro-Cruz, Sandra María Pinto-Cardoso, Vilma Carolina Bekker-Méndez
May 10, 2022
INTRODUCTION: In Mexico, HIV genotyping is performed in people living with HIV (PLWH) failing their first-line antiretroviral (ARV) regimen; it is not routinely done for all treatment-naive PLWH before ARV initiation. The first...
Antiretroviral Therapy Gag HIV drug resistance mutations HIV genotyping human immunodeficiency virus Next generation sequencing Protease Adult Anti-HIV Agents Anti-Retroviral Agents Drug Resistance Viral Female Genotype HIV Infections HIV Protease HIV-1 Humans Male Mexico Mutation Peptide Hydrolases Reverse Transcriptase Inhibitors
Treatment outcomes among adults with HIV/non-communicable disease multimorbidity attending integrated care clubs in Cape Town, South Africa.
BACKGROUND: The growing burden of the HIV and non-communicable disease (NCD) syndemic in Sub- Saharan Africa has necessitated introduction of integrated models of care in order to leverage existing HIV care infrastructure for...
Efficacy of HIV interventions in African fishing communities
OBJECTIVES: This systematic review aims to qualitatively synthesize existing evidence on the efficacy of HIV interventions in African fishing communities. METHODS: Five databases (NCBI PubMed, EMBASE, Web of Science Core...
The renal-bone axis in older people living with HIV on stable antiretroviral therapy
Elena Alvarez, Lucy Campbell, Willard Tinago, Alejandro Garcia-Leon, Ian Walsh, Jennifer J Brady, Keith Burling, Sebastian Noe, Marie F Neuville, Francois Jouret, Farid Jamshidian, Hiba Graham, Martin Rhee, Paddy W Mallon, Frank A Post
Aug 25, 2022
BACKGROUND: Data on low bone mineral density (BMD) in people living with HIV (PLWH) are mainly derived from younger adults; little is known about how antiretroviral therapy (ART) and alterations in the renal-bone axis relate to...
The future of financing for HIV services in Uganda and the wider sub-Saharan Africa region
Whilst multi-lateral funding for HIV/AIDS dramatically increased from 2004 to 2008, it has largely plateaued in the last 8 years. Across sub-Saharan Africa, up to 20 % of total spending on health is used for HIV services, and of...
Financing HIV Sustaining Treatment Uganda Africa South of the Sahara Anti-HIV Agents Delivery of Health Care Financial Support Financing Government Financing personal HIV Infections Health Care Costs Health Expenditures Health Services Health Services Accessibility Humans insurance health International Cooperation Uganda
Effectiveness of three delivery models for promoting access to pre-exposure prophylaxis in HIV-1 serodiscordant couples in Nigeria.
Morenike Oluwatoyin Folayan, Sani Aliyu, Ayodeji Oginni, Oliver Ezechi, Grace Kolawole, Nkiru Ezeama, Nancin Dadem, James Anenih, Matthias Alagi, Etim Ekanem, Evaristus Afiadigwe, Rose Aguolu, Tinuade Oyebode, Alero Babalola-Jacobs, Atiene Sagay, Chidi Nweneka, Hadiza Kamofu, John Idoko
Jun 07, 2022
OBJECTIVES: To evaluate the effectiveness of three models for pre-exposure prophylaxis (PrEP) service delivery to HIV-1 serodiscordant couples in Nigeria. METHODS: 297 heterosexual HIV-1 serodiscordant couples were recruited...